solriamfetol dose b
solriamfetol dose b: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Lead developer: Axsome Therapeutics, Inc. (AXSM)
Development Pipeline (1)
| Company | Phase |
|---|---|
| Axsome Therapeutics, Inc. (AXSM) | Phase 4 |
Clinical Trials (1)
A Phase 3, Randomized, 6-Week, Double-blind, Placebo- Controlled Trial of Solriamfetol in Adolescents Aged 12 to <18 Years With Attention Deficit Hyperactivity Disorder (ADHD)
Frequently asked questions
Who is developing solriamfetol dose b?
solriamfetol dose b is being developed by Axsome Therapeutics, Inc..
How many clinical trials involve solriamfetol dose b?
BioSniper tracks 1 clinical trial involving solriamfetol dose b.
Analyze Axsome Therapeutics, Inc. & solriamfetol dose b with AI
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
- 200 free AI credits / month to run live multi-agent analysis
- Watchlist, catalyst alerts & the biotech event calendar
- Full pipeline, financials & FDA data on every company